ARTL
- Artelo Biosciences, Inc.
()
Overview
Company Summary
Artelo Biosciences, Inc. (ARTL) is a biopharmaceutical company dedicated to discovering and developing innovative therapies in the field of cannabinoid-based medicines. The company focuses on combining the therapeutic potential of cannabinoids with other existing treatment options to address various unmet medical needs.
Artelo Biosciences primarily conducts research and development to create new drug candidates that can potentially treat serious conditions such as cancer, pain, and inflammation. The company leverages its expertise in cannabinoid science and drug development to design and test novel compounds that have the potential to offer therapeutic benefits in these areas.
One of the key aspects of Artelo Biosciences' approach is the use of a proprietary platform technology called ART26.12, which involves the modulation of the endocannabinoid system, a signaling system in the human body that plays a crucial role in maintaining overall health and homeostasis. By targeting specific components of this system, the company aims to develop drugs that can effectively treat different diseases and conditions.
Additionally, Artelo Biosciences collaborates with leading academic institutions, research organizations, and contract manufacturers to advance its drug development programs. The company also actively seeks partnerships and collaborations with other pharmaceutical firms to enhance its capabilities and broaden the potential impact of its therapies.
In summary, Artelo Biosciences is focused on developing cannabinoid-based medicines and leveraging its proprietary platform technology to create new drug candidates that have the potential to address various diseases and improve patient outcomes.